GlobeNewswire by notified

Patients will benefit if Europe modernizes its policy framework to reflect the distinct promise of cell and gene therapy, the Alliance for Regenerative Medicine will highlight in 29 November EU Parliament event

Share

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Patients will benefit if Europe modernizes its policy framework to reflect the distinct promise of cell and gene therapy, the Alliance for Regenerative Medicine will highlight in 29 November EU Parliament event

Event will feature first pediatric patient to receive a CAR-T therapy and focus on policy recommendations to reverse Europe’s declining competitiveness

BRUSSELS – 24 November 2022

The European Union can reverse its declining competitiveness and ensure patient access to transformative treatments if it modernizes its policy and regulatory framework to reflect the distinct promise of cell and gene therapies as the future of medicine, the Alliance for Regenerative Medicine (ARM) will say during an event at the EU Parliament on 29 November.  

ARM and Member of the European Parliament Dr. Stelios Kympouropoulos of the European People’s Party will highlight concerning trends for advanced therapy medicinal product (ATMP) developers, clinical trials, and investment in the EU.

“Cell and gene therapies represent tremendous hope for patients with serious diseases in the EU – but if we don’t act to ensure patients have access, hope is all we will have,” said MEP Kympouropoulos, who lives with spinal muscular atrophy, a rare genetic neuromuscular disease. MEP Kympouropoulos recently signed a letter with 25 MEPs asking the European Commission not to undermine the European pharmaceutical and biotechnology sectors with its upcoming proposal to revise the EU pharmaceuticals legislation.

The 29 November event – The Future of ATMPs in Europe -- will focus on the first-in-a-generation revision of the EU pharmaceuticals legislation, the future implementation of the EU Regulation on Health Technology Assessment, and other key policy initiatives that will determine the role of cell and gene therapies in Europe’s healthcare landscape for years to come.

“If Europe modernizes its policy and regulatory framework to truly embrace ATMPs as the future of medicine, European patients living with cancer, rare diseases, and other serious and often life-threatening disorders will benefit tremendously,” said Timothy D. Hunt, chief executive officer of ARM. “The same policies and approaches that brought us yesterday’s biomedical innovation simply will not work for the cell and gene therapies of today and tomorrow. The EU has led before -- and can lead once again -- but the time to act is now.”

Seven of the 23 ATMPs that have been approved in the EU have been withdrawn from the market. ARM’s data further illustrates the sector’s struggles in Europe:

  • As of the end of June 2022, the number of ongoing industry clinical trials in Europe increased by just 2% and the number of developers headquartered in Europe declined by 2% compared to five years ago, while the numbers in North America increased by 41% and 42%, respectively, and the numbers in Asia-Pacific increased by 74% and 271%, respectively.
  • Europe accounted for just 11% of new trials starting in the first half of 2022, with only two phase 1 trials.

More information can be found in ARM’s H1 2022 Sector Report, “Regenerative Medicine: The Pipeline Momentum Builds.

During the event, ARM will release policy recommendations that would modernize the EU’s regulatory and access frameworks, and encourage cell and gene therapy companies to develop, test, and commercialize their therapies in the region.

Other speakers include Emily Whitehead, who was the first pediatric patient globally to receive a CAR-T therapy, an engineered cell therapy that attacks cancer cells. Ten years later, she is considered cured of leukemia.

“Getting to travel and advocate for this treatment in Europe is an honor,” said Whitehead, now 17. “It is my hope that every child in the world can someday have access to these treatments and get back to their normal lives and be happy and healthy.”

Emily’s father, Tom Whitehead, president and co-founder of the Emily Whitehead Foundation, will also speak. “We have heard from many families from Europe since Emily had her success with CAR-T cell therapy, and we are honored to share our story to hopefully get more access to these new amazing cancer treatments so more patients can not only survive their cancer but thrive in life after.”

Media inquiries

For more information or for media requests and registration, please contact Stephen Majors, Senior Director of Public Affairs for ARM, at smajors@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organisation dedicated to realizing the promise of advanced therapy medicinal products (ATMPs). ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives in Europe and internationally to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-engineered therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing ATMPs. In its 13-year history, ARM has become the global voice of the sector, representing the interests of 475+ members worldwide and 80+ members across 15 European countries, including small and large companies, academic research institutions, major medical centres and patient groups. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye